医学
拓扑替康
吉西他滨
卵巢癌
肿瘤科
阿霉素
内科学
化疗
癌症
作者
D. Pectasides,Amanda Psyrri,Melina Pectasides,Theofanis Economopoulos
标识
DOI:10.1517/14656566.7.8.975
摘要
Ovarian cancer is more fatal than all the other gynaecolological malignancies combined. Although most patients respond to first-line combination chemotherapy, the vast majority (50 – 75%) of patients with advanced disease will relapse. The management of patients with recurrent ovarian cancer is based on their response profile to platinum: patients with platinum-sensitive disease can be rechallenged with platinum-based chemotherapy, whereas the management of patients with platinum-resistant or -refractory disease remains an area of active investigation. In this review, the data for second-line therapy in this latter group of patients will be summarised and recommendations for their optimal management will be made.
科研通智能强力驱动
Strongly Powered by AbleSci AI